Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

Inclusion Criteria: Subjects meeting all of the following criteria will be considered for enrolment to the trial: * Male or female ≥ 18 years * IOP in the study eye ≤ 21mmHg * Primary ischaemic CRVO or conversion to ischaemic CRVO in the study eye for no longer than 4 weeks * Best-corrected visual acuity (BCVA) ETDRS letter score \< 35 (\< 20/200 Snellen equivalent) in the study eye * ≥ 10-disc area of retinal capillary obliteration on fluorescein fundus angiography in the study eye (central fundus: macular area as defined by the optic disc and the arcades, an approximate 6000 micron circle around the fovea) and/or large, confluent retinal haemorrhages in the study eye Must be accompanied by 4 or more out of 6 following criteria: * A relative afferent pupillary defect (with a normal fellow eye) * ≥ 10 cotton-wool-spots in the study eye * Venous tortuosity in the study eye * Peripheral visual field defects corresponding to ischaemia (Goldmann perimeter or other semi-automatic kinetic methods) in the study eye * Engorged vessels on iris and/or in the chamber angle in the study eye * Detectable anterior chamber flare in the study eye Exclusion Criteria: Subjects presenting 1 or more of the following criteria will not be enrolled in the trial: * Ocular conditions with a poorer prognosis in the fellow eye than in the study eye * Primary or secondary glaucoma in the study eye * Prior or concomitant ocular treatment with anti-VEGF in the study eye (ranibizumab/bevacizumab is not allowed within the last 45 days, aflibercept within the last 90 days) before screening visit * Use of anti-VEGF treatment in the fellow eye during the trial * Previous use of intraocular corticosteroids at any time or use of periocular corticosteroids in the study eye within 90 days prior to screening visit * History of idiopathic or autoimmune uveitis in either eye * Presence of NVD, NVE or anterior segment neovascularisation (NVA or NVI) in the study eye * Previous PRP in the study eye * Intraocular surgery (other than intravitreal anti-VEGF treatment) or laser treatment in the study eye within the past 90 days before screening visit * Patients with a history of breast cancer